866-945-0263 | enquiries@arrowheadpublishers.com

Press Releases

June 16, 2016

 
Genelex CEO Kristine Ashcraft to Share Insights on Future of Pharmacogenomics at 8th Annual Personalized & Precision Medicine Conference

Recently, Genelex responded to requests by various stakeholders in the personalized and precision medicine industry by creating High Risk PGx Drug Charts, which are available on the YouScript software. By providing these helpful resources when interpreting PGx results with these resources, Genelex hopes to improve the evaluation of drug-drug, drug-gene, and cumulative interactions in real-time.

October 11, 2013

TBI Research News Out of Canada Discusses Ideas for Improving Post TBI Brain Development
 
For the first time, scientists at Toronto Rehab have found that in people with chronic moderate-severe traumatic brain injury (TBI), atrophy (shrinkage) in the brain may be countered by participating in environmental enrichment – increased physical, social and cognitive stimulation. 
 

September 27, 2013

Microelectrode Arrays for Pain Research and Drug Development

Large amounts of information on the cellular and molecular mechanisms involved in sensory processing in the peripheral nervous system have been gained in vitro using neurons isolated from dorsal root ganglia (DRG). Electrophysiological recordings from cultured DRG neurons were mainly obtained by the use of patch-clamp, an approach offering a level of throughput often incompatible with the objectives of the pharmaceutical industry.

September 9, 2013

How Will Next Gen Sequencing Tests be Evaluated by Payers?
 
While molecular diagnostics offer tremendous promise for improving health and offsetting costs in the oncology setting, the benefits and harms of testing are often not well known in terms that are meaningful to stakeholders. Tests are often presumed to offer clinical benefits, and may even be taken up into clinical practice based on that assumption. 
 

August 1, 2013

Lessons from Successful Molecular Diagnostics Launches
 
In July, Verinata Health announced an agreement with Teva Pharmaceutical Industries in collaboration with MOR institute data to commercialize the verifi® prenatal test in Israel.
 

Contact Us

PO Box 96
Chanhassen, MN 55317 USA
866-945-0263
www.arrowheadpublishers.com
enquiries@arrowheadpublishers.com

Speaker Opportunities

If you are interested in speaking at one of Arrowhead's conferences or would like to suggest a conference theme for which you have particular expertise, we'd like to hear from you.

Sponsor/Exhibitor Opportunities

Arrowhead sponsorship and exhibitor levels are designed to give your organization the highest level of exposure and opportunity to market products and branding in an environment that is targeted toward facilitating professional networking. We can also build tailor-made packages that will meet your organization's marketing budget and goals. Arrowhead sponsorships are proven to help grow businesses through direct and targeted exposure to industry leaders and decision makers. To gain critical industry exposure via our sponsorship and exhibiting opportunities, please contact us.